Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib + Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)
NCT06811116Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sapanisertib in hepatocellular carcinoma (HCC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Dose-Limiting Toxicities at 2 years and Progression-Free Survival at 2 years. Started Nov 2025; status: recruiting.
02
Drugs
sapanisertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06811116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811116.